Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Eschmann

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Lung Cancer (Amsterdam, Netherlands)|November 30, 2006
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancerS M Eschmann, G Friedel, F Paulsen, et al.
Der Radiologe|September 25, 2007
[Cost considerations for whole-body MRI and PET/CT as part of oncologic staging]C Plathow, M Walz, M P Lichy, et al.
Nuklearmedizin. Nuclear Medicine|June 2, 2010
Lesion concordance, image quality and artefacts in PET/CT: results of a multicenter studyH Stergar, B J Krause, S M Eschmann, et al.
Nuclear Medicine Communications|August 21, 2004
The benefit of functional-anatomical imaging with [18F]fluorodeoxyglucose utilizing a dual-head coincidence gamma camera with an integrated X-ray transmission system in non-small cell lung cancerSusanne M Eschmann, Michael Bitzer, Frank Paulsen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2006
Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancerAnna C Pfannenberg, Philip Aschoff, Klaus Brechtel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 4, 2006
Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imagingKlaus Brechtel, Magnus Klein, Monika Vogel, et al.
Urology|June 19, 2007
Morphologic, functional, and metabolic magnetic resonance imaging-guided prostate biopsy in a patient with prior negative transrectal ultrasound-guided biopsies and persistently elevated prostate-specific antigen levelsMatthias P Lichy, Aristotelis G Anastasiadis, Philip Aschoff, et al.
Nuklearmedizin. Nuclear Medicine|October 17, 2007
Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancerS M Eschmann, A C Pfannenberg, A Rieger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 5, 2005
Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?S M Eschmann, G Friedel, F Paulsen, et al.
Radiation Oncology (London, England)|November 20, 2009
[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planningBarbara Gehler, Frank Paulsen, Mehmet O Oksüz, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Lung Cancer (Amsterdam, Netherlands)|November 30, 2006
Repeat 18F-FDG PET for monitoring neoadjuvant chemotherapy in patients with stage III non-small cell lung cancerS M Eschmann, G Friedel, F Paulsen, et al.
Der Radiologe|September 25, 2007
[Cost considerations for whole-body MRI and PET/CT as part of oncologic staging]C Plathow, M Walz, M P Lichy, et al.
Nuklearmedizin. Nuclear Medicine|June 2, 2010
Lesion concordance, image quality and artefacts in PET/CT: results of a multicenter studyH Stergar, B J Krause, S M Eschmann, et al.
Nuclear Medicine Communications|August 21, 2004
The benefit of functional-anatomical imaging with [18F]fluorodeoxyglucose utilizing a dual-head coincidence gamma camera with an integrated X-ray transmission system in non-small cell lung cancerSusanne M Eschmann, Michael Bitzer, Frank Paulsen, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 10, 2006
Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancerAnna C Pfannenberg, Philip Aschoff, Klaus Brechtel, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 4, 2006
Optimized contrast-enhanced CT protocols for diagnostic whole-body 18F-FDG PET/CT: technical aspects of single-phase versus multiphase CT imagingKlaus Brechtel, Magnus Klein, Monika Vogel, et al.
Urology|June 19, 2007
Morphologic, functional, and metabolic magnetic resonance imaging-guided prostate biopsy in a patient with prior negative transrectal ultrasound-guided biopsies and persistently elevated prostate-specific antigen levelsMatthias P Lichy, Aristotelis G Anastasiadis, Philip Aschoff, et al.
Nuklearmedizin. Nuclear Medicine|October 17, 2007
Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancerS M Eschmann, A C Pfannenberg, A Rieger, et al.
European Journal of Nuclear Medicine and Molecular Imaging|November 5, 2005
Is standardised (18)F-FDG uptake value an outcome predictor in patients with stage III non-small cell lung cancer?S M Eschmann, G Friedel, F Paulsen, et al.
Radiation Oncology (London, England)|November 20, 2009
[68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planningBarbara Gehler, Frank Paulsen, Mehmet O Oksüz, et al.
Pageof 4